Recent advancements in combination subunit vaccine development

References

• Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. Laboratory efforts to cultivate noroviruses. J Gen Virol 2004; 85:79-87; PMID:14718622; http://dx.doi.org/10.1099/vir.0.19478-0
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. Subviral particle as vaccine and vaccine platform. Curr Opin Virol 2014; 6C:24-33; http://dx.doi.org/10.1016/j.coviro.2014.02.009
   Web of Science ®Google Scholar
• Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013; 31:654-63; PMID:24125746; http://dx.doi.org/10.1016/j.tibtech.2013.09.002
   PubMed Web of Science ®Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012; 31:58-83; PMID:23142589; http://dx.doi.org/10.1016/j.vaccine.2012.10.083
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:6527-32; PMID:1328679
   PubMed Web of Science ®Google Scholar
• Zeng CQ, Wentz MJ, Cohen J, Estes MK, Ramig RF. Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants. J Virol 1996; 70:2736-42; PMID:8627747
   PubMed Web of Science ®Google Scholar
• Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, Buonaguro L. Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol 2015; 87:102-11; PMID:24797918; http://dx.doi.org/10.1002/jmv.23973
   PubMed Web of Science ®Google Scholar
• Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004; 576:174-8; PMID:15474033; http://dx.doi.org/10.1016/j.febslet.2004.09.009
   PubMed Web of Science ®Google Scholar
• Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X. Noroviral P particle: Structure, function and applications in virus-host interaction. Virology 2008; 382:115-23; PMID:18926552; http://dx.doi.org/10.1016/j.virol.2008.08.047
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005; 79:14017-30; PMID:16254337; http://dx.doi.org/10.1128/JVI.79.22.14017-14030.2005
   PubMed Web of Science ®Google Scholar
• Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology 2011; 410:345-52; PMID:21185050; http://dx.doi.org/10.1016/j.virol.2010.11.017
   PubMed Web of Science ®Google Scholar
• Bereszczak JZ, Barbu IM, Tan M, Xia M, Jiang X, van Duijn E, Heck AJ. Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry. J Struct Biol 2012; 177:273-82; PMID:22266117; http://dx.doi.org/10.1016/j.jsb.2012.01.005
   PubMed Web of Science ®Google Scholar
• Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; http://dx.doi.org/10.1016/j.vaccine.2004.11.064
   PubMed Web of Science ®Google Scholar
• Wang L, Huang P, Fang H, Xia M, Zhong W, McNeal MM, Jiang X, Tan M. Polyvalent complexes for vaccine development. Biomaterials 2013; 34:4480-92; PMID:23498893; http://dx.doi.org/10.1016/j.biomaterials.2013.02.041
   PubMed Web of Science ®Google Scholar
• Wang L, Xia M, Huang P, Fang H, Cao D, Meng XJ, McNeal M, Jiang X, Tan M. Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials 2014; 35:8427-38; PMID:24985736; http://dx.doi.org/10.1016/j.biomaterials.2014.06.021
   PubMed Web of Science ®Google Scholar
• Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology 2010; PMID:20872839
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180-4; PMID:1334560; http://dx.doi.org/10.1073/pnas.89.24.12180
   PubMed Web of Science ®Google Scholar
• Jagu S, Kwak K, Garcea RL, Roden RB. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010; 28:4478-86; PMID:20434552; http://dx.doi.org/10.1016/j.vaccine.2010.04.039
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; http://dx.doi.org/10.1016/S0140-6736(04)17398-4
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178-80; PMID:6318124; http://dx.doi.org/10.1038/307178a0
   PubMed Web of Science ®Google Scholar
• Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgraduate Med J 1987; 63(Suppl 2):169-77; PMID:3317357
   PubMed Web of Science ®Google Scholar
• Proffitt A. First HEV vaccine approved. Nat Biotechnol 2012; 30:300; PMID:22491268; http://dx.doi.org/10.1038/nbt0412-300a
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178-87; PMID:22150036; http://dx.doi.org/10.1056/NEJMoa1101245
   PubMed Web of Science ®Google Scholar
• Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine 2013; 31:3872-8; PMID:23827313; http://dx.doi.org/10.1016/j.vaccine.2013.06.062
   PubMed Web of Science ®Google Scholar
• Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011; 29:7357-63; PMID:21807052; http://dx.doi.org/10.1016/j.vaccine.2011.07.080
   PubMed Web of Science ®Google Scholar
• Tan M, Huang P, Xia M, Fang PA, Zhong W, McNeal M, Wei C, Jiang W, Jiang X. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011; 85:753-64; PMID:21068235; http://dx.doi.org/10.1128/JVI.01835-10
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) 2012; 7:889-97; PMID:22734641
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. Nanoparticles of Norovirus. In: Khudyakov Y, Pumpens P, eds. Viral Nanptechnology. Norwich, UK: CRC Press, Taylor &Francis Group, 2015:363-71.
   Google Scholar
• Xia M, Tan M, Wei C, Zhong W, Wang L, McNeal M, Jiang X. A candidate dual vaccine against influenza and noroviruses. Vaccine 2011; 29:7670-7; PMID:21839795; http://dx.doi.org/10.1016/j.vaccine.2011.07.139
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccines 2010; 6:90-6; PMID:19806009; http://dx.doi.org/10.4161/hv.6.1.9677
   PubMed Web of Science ®Google Scholar
• Tan M, Xia M, Huang P, Wang L, Zhong W, McNeal M, Wei C, Jiang X. Norovirus P Particle as a Platform for Antigen Presentation. Procedia Vaccinol 2011; 4:19-26; http://dx.doi.org/10.1016/j.provac.2011.07.004
   Google Scholar
• Gosling R, von Seidlein L. The future of the RTS,S/AS01 malaria vaccine: an alternative development plan. PLoS Med 2016; 13:e1001994; PMID:27070151; http://dx.doi.org/10.1371/journal.pmed.1001994
   PubMed Web of Science ®Google Scholar
• Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11:e1001685; PMID:25072396; http://dx.doi.org/10.1371/journal.pmed.1001685
   PubMed Web of Science ®Google Scholar
• Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31-45; PMID:25913272; http://dx.doi.org/10.1016/S0140-6736(15)60721-8
   PubMed Web of Science ®Google Scholar
• Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95; PMID:23136909; http://dx.doi.org/10.1056/NEJMoa1208394
   PubMed Web of Science ®Google Scholar
• Brown MJ. Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol 2009; 6:639-47; PMID:19707182; http://dx.doi.org/10.1038/nrcardio.2009.156
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, Bangala Y, Guessous I, Muller P, Willers J, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3:e2547; PMID:18575629; http://dx.doi.org/10.1371/journal.pone.0002547
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Muller P, Bachmann MF. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005; 35:2031-40; PMID:15971275; http://dx.doi.org/10.1002/eji.200526285
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63; PMID:10502819; http://dx.doi.org/10.1038/13484
   PubMed Web of Science ®Google Scholar
• De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, Min Jou W, Saelens X, Fiers W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006; 24:544-51; PMID:16169634; http://dx.doi.org/10.1016/j.vaccine.2005.08.061
   PubMed Web of Science ®Google Scholar
• Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Exp Rev Vaccines 2009; 8:499-508; PMID:19348565; http://dx.doi.org/10.1586/erv.09.6
   PubMed Web of Science ®Google Scholar
• Gong X, Yin H, Shi Y, He X, Yu Y, Guan S, Kuai Z, Haji NM, Haji NM, Kong W, et al. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. Emerg Microbes Infect 2016; 5:e51; PMID:27222326; http://dx.doi.org/10.1038/emi.2016.51
   PubMed Web of Science ®Google Scholar
• Yu Y, Fu L, Shi Y, Guan S, Yang L, Gong X, Yin H, He X, Liu D, Kuai Z, et al. Elicitation of HIV-1 neutralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P particles. Immunol Lett 2015; 168:271-8; PMID:26455781; http://dx.doi.org/10.1016/j.imlet.2015.10.003
   PubMed Web of Science ®Google Scholar
• Jiang L, Fan R, Sun S, Fan P, Su W, Zhou Y, Gao F, Xu F, Kong W, Jiang C. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine 2015; 33:6596-603; PMID:26529072; http://dx.doi.org/10.1016/j.vaccine.2015.10.104
   PubMed Web of Science ®Google Scholar
• Wang L, Cao D, Wei C, Meng XJ, Jiang X, Tan M. A dual vaccine candidate against norovirus and hepatitis E virus. Vaccine 2014; 32:445-52; PMID:24291540; http://dx.doi.org/10.1016/j.vaccine.2013.11.064
   PubMed Web of Science ®Google Scholar
• Xia M, Wei C, Wang L, Cao D, Meng XJ, Jiang X, Tan M. A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus. Vaccine 2016; 34:905-13; PMID:26778421; http://dx.doi.org/10.1016/j.vaccine.2015.12.068
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. The formation of P particle increased immunogenicity of norovirus P protein. Immunology 2012; 136:28-9; PMID:22257239; http://dx.doi.org/10.1111/j.1365-2567.2012.03555.x
   PubMed Web of Science ®Google Scholar
• Xia M, Wei C, Wang L, Cao D, Meng XJ, Jiang X, Tan M. Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus. Sci Rep 2016; 6:25735; PMID:27194006; http://dx.doi.org/10.1038/srep25735
   PubMed Web of Science ®Google Scholar